Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma

Inclusion Criteria: * Both males and females ≥ eighteen years of age * Clinical diagnosis of urothelial carcinoma of the renal pelvis and/or ureter. Clinical diagnosis of urothelial carcinoma may be based upon radiographic, pathologic or cytological findings alone or in combination with one another. No other histology is allowed. * The TNM stage of the subject's disease (using the American Joint Committee on Cancer \[AJCC\] Cancer Staging Manual, 8th Edition) must be Tis, Ta, T1, T2, or T3, N0, M0. Subjects may have either a high-grade or low-grade tumor. * ECOG performance status of 0-2 * Written informed consent obtained from the subject and the ability for the subject to comply with all the study-related procedures. * Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy prior to and for at least 3 months after mitomycin C instillation to minimize the risk of pregnancy. Prior to study enrollment, women of childbearing potential must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy. * Males with female partners of child-bearing potential must agree to use physician-approved contraceptive methods (e.g., abstinence, condoms, vasectomy) should avoid conceiving children prior to and for 3 months following mitomycin C instillation * Subjects must have hemoglobin ≥ 9 g/dL and a platelet count ≥ 100,000/μL. Exclusion Criteria: * Activ…